Efficacy and Safety Study of PEX168 in Combination Therapy Diabetes Mellitus Type 2 Patients With Metformin
A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It enrolled 587 participants.
Also called NCT02477969
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 587 participants
- Registry
-
NCT02477969
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Unknown status
Technical summary
Registry record NCT02477969. Randomized; triple masking; primary purpose treatment. Start 2014-02-27 (actual); primary completion 2016-06-22 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety Study of PEX168 in Combination Therapy Diabetes Mellitus Type 2 Patients With Metformin
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- PEX168(100µg)
- Intervention (Drug)
- PEX168(200µg)
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Metformin
- Lead sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Record details
- Record id
cardio:ct-nct02477969- Content hash
ca9a86778c66a235ed2d630e6d5e53ab828d9440278225b75a0213369e048001